Do emerging mechanism-based therapies reduce triglycerides and acute pancreatitis risk in patients with chylomicronemia syndromes?
Emerging mechanism-based therapies offer targeted approaches to reduce triglycerides and acute pancreatitis risk in severe hypertriglyceridemia.
These emerging mechanism-based therapies are reshaping the management of severe hypertriglyceridemia, offering targeted approaches to reduce triglycerides and acute pancreatitis risk. Ongoing studies will clarify long-term safety, durability of response, and optimal patient selection, providing a framework for improved clinical outcomes.
D’Erasmo et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: